ImmunovantIMVT stock shot to a two-year high Wednesday on what an analyst called "highly compelling" results for its experimental rheumatoid arthritis treatment. The company tested the drug, IMVT-1402 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results